Innate Pharma (IPHA) Non-Current Assets (2017 - 2025)

Innate Pharma has reported Non-Current Assets for 9 years, with the latest figure at $18.6 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Assets fell 31.12% year-over-year to $18.6 million; the trailing twelve-month figure through Dec 2025 stood at $18.6 million (down 31.12% YoY), and the FY2025 full-year result was $18.6 million, down 31.12% from the prior year.
• Non-Current Assets for Q4 2025 stood at $18.6 million, down from $31.6 million in the prior quarter.
• The five-year high for Non-Current Assets was $164.4 million in Q2 2021, with the low at $18.6 million in Q4 2025.
• Historically, Non-Current Assets has averaged $69.8 million across 5 years, with a median of $51.2 million in 2023.
• The largest YoY upside for Non-Current Assets was 7.44% in 2021 against a maximum downside of 99.9% in 2021.
• Innate Pharma's Non-Current Assets stood at $147.8 million in 2021, then slumped by 58.97% to $60.7 million in 2022, then slumped by 51.81% to $29.2 million in 2023, then fell by 7.47% to $27.1 million in 2024, then plunged by 31.12% to $18.6 million in 2025.
• The last three Non-Current Assets figures came in at $18.6 million (Q4 2025), $31.6 million (Q2 2025), and $27.1 million (Q4 2024), per Business Quant data.